Clinical Trial Update: Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement [Phase 1]

View source ↗

Summary

A completed Phase 1 dose-escalation study evaluating intravenous ALN-VSP02 in patients with advanced solid tumors involving the liver, assessing safety, tolerab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ALN-VSP02

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED